NCT07203755 - Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions

Diphtheria, Tetanus and Acellular PertussisEpidemic MeningitisHaemophilus Influenzae Type B Infection

Interventions

BIOLOGICAL

Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)

1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0

BIOLOGICAL

DTcP-Hib-MCV4

1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0

BIOLOGICAL

DTcP-Hib-MCV4

1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0

BIOLOGICAL

DTcP-Hib-MCV4

3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

BIOLOGICAL

DTcP-Hib-MCV4

3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

BIOLOGICAL

Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)

3 doses of DTcP (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

BIOLOGICAL

Haemophilus influenzae type b (Conjugate) (Hib)

3 doses of Hib (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

BIOLOGICAL

Meningococcal Group ACYW135 (Conjugate) (MCV4)

3 doses of MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.

BIOLOGICAL

MCV4

3 doses of MCV4 (0.5ml) at 0, 1, and 2 months, followed by a booster dose at 12 months of age.

BIOLOGICAL

MCV4

3 doses of MCV4 (0.5ml) at 0, 2, and 4 months.

OTHER

Sodium Chloride Injection (0.9%) (Saline Solution) (NS)

3 doses of NS (0.5ml) at 0, 2, and 4 months.